In Brief: Bayer Cipro
Executive Summary
Bayer Cipro: Ciprofloxacin approved June 5 for treatment of mild to moderate acute sinusitis caused by S. pneumoniae, H. influenzae and M. catarrhalis at a recommended adult dosage of 500 mg b.i.d. for 10 days. A trial comparing Cipro to cefuroxime for acute sinusitis demonstrated 77% resolution for Cipro and 71% for cefuroxime after 30 days of follow-up, Bayer says. Another comparative trial showed 96% resolution for Cipro and 90% for clarithromycin at 30 days...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth